Unknown

Dataset Information

0

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON).


ABSTRACT: The Dermatologic Oncology Group of Japan Clinical Oncology Group has started a randomized phase III trial to confirm the superiority of adjuvant therapy with locoregional interferon beta in overall survival over surgery alone for patients with pathological stage II/III cutaneous melanoma (JCOG1309). Patients in the interferon beta arm receive intra- or subcutaneous injections of interferon beta directly into the surgical site at a flat dose of 3 million units once per day. Treatment is repeated for 10 consecutive days every 8 weeks for a total of 3 courses during the induction phase, then 1-day injection every 4 weeks for 2.5 years. A total of 240 patients will be accrued from 17 Japanese institutions within 6.5 years. Primary endpoint is overall survival. Secondary endpoints are relapse-free survival, distant metastasis-free survival, pattern of recurrence, and adverse events. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000017494 [http://www.umin.ac.jp/ctr/index.htm].

SUBMITTER: Namikawa K 

PROVIDER: S-EPMC5896686 | biostudies-other | 2017 Jul

REPOSITORIES: biostudies-other

altmetric image

Publications

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON).

Namikawa Kenjiro K   Tsutsumida Arata A   Mizutani Tomonori T   Shibata Taro T   Takenouchi Tatsuya T   Yoshikawa Shusuke S   Kiyohara Yoshio Y   Uchi Hiroshi H   Furue Masutaka M   Ogata Dai D   Tsuchida Tetsuya T   Yamazaki Naoya N  

Japanese journal of clinical oncology 20170701 7


The Dermatologic Oncology Group of Japan Clinical Oncology Group has started a randomized phase III trial to confirm the superiority of adjuvant therapy with locoregional interferon beta in overall survival over surgery alone for patients with pathological stage II/III cutaneous melanoma (JCOG1309). Patients in the interferon beta arm receive intra- or subcutaneous injections of interferon beta directly into the surgical site at a flat dose of 3 million units once per day. Treatment is repeated  ...[more]

Similar Datasets

| S-EPMC9844053 | biostudies-literature
| S-EPMC5648545 | biostudies-literature
| S-EPMC6693227 | biostudies-literature
| S-EPMC8434723 | biostudies-literature
| S-EPMC6551453 | biostudies-literature
| S-EPMC9297464 | biostudies-literature
| S-EPMC4760342 | biostudies-literature
| S-EPMC8158378 | biostudies-literature
| S-EPMC6094670 | biostudies-literature
| S-EPMC8649038 | biostudies-literature